1089. Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)

BACKGROUND: ADG20 is a fully human IgG1 monoclonal antibody engineered to have potent and broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other SARS-like CoVs with pandemic potential as well as an extended-half-life. ADG20 is administered intramuscularly...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Wart, Scott A, Tarbell, Evan D, Narayan, Kristin, Walker, Laura M, Connolly, Lynn E, Ambrose, Paul G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644371/
http://dx.doi.org/10.1093/ofid/ofab466.1283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644371/
http://dx.doi.org/10.1093/ofid/ofab466.1283

Ejemplares similares